Abstract: Ingestible devices can directly deliver therapeutic agents to desired tissue(s) of the GI tract of a subject, such as the submucosa, the mucosa, and/or the mucus layer of the GI tract, and methods of using the same. The ingestible devices can deliver therapeutic agents in a safe, effective, and reliable manner. The disclosure also provides pharmaceutical compositions for use in methods of treating a disease or condition.

Abstract: Ingestible devices can directly deliver therapeutic agents to desired tissue(s) of the GI tract of a subject, such as the submucosa, the mucosa, and/or the mucus layer of the GI tract, and methods of using the same. The ingestible devices can deliver therapeutic agents in a safe, effective, and reliable manner. The disclosure also provides pharmaceutical compositions for use in methods of treating a disease or condition in a subject in need thereof.

Abstract: A dry powder inhaler includes an inhalation channel connected to a mouthpiece, a container for storing a powdered medicament, a de-agglomerator with a vortex chamber located at an end of the inhalation channel, a metering device including a shuttle having a dosing recess. The shuttle is movable between a filling position, in which the dosing recess is in alignment with an opening of the container, and an inhalation position, in which the dosing recess is in alignment with the vortex chamber. The opening of the container is elongated along a major axis and the dosing recess is elongated along a main axis and, when the shuttle is in the filling position, an edge of the opening of the container encloses the dosing recess.

Abstract: Ingestible devices can directly deliver therapeutic agents to desired tissue(s) of the GI tract of a subject, such as the submucosa, the mucosa, and/or the mucus layer of the GI tract, and methods of using the same. The ingestible devices can deliver therapeutic agents in a safe, effective, and reliable manner. The disclosure also provides pharmaceutical compositions for use in methods of treating a disease or condition in a subject in need thereof.

Abstract: Ingestible devices can directly deliver therapeutic agents to desired tissue(s) of the GI tract of a subject, such as the submucosa, the mucosa, and/or the mucus layer of the GI tract, and methods of using the same. The ingestible devices can deliver therapeutic agents in a safe, effective, and reliable manner. The disclosure also provides pharmaceutical compositions for use in methods of treating a disease or condition in a subject in need thereof.

Abstract: An aerosol preparation assembly includes an entrainment chamber defining an entrainment volume. The entrainment chamber includes a gas inlet port, an aerosol inlet port and an outlet port. The entrainment chamber is configured such that a velocity of a flow of a gas within the entrainment volume is less than a velocity of the flow of the gas within the gas inlet port. The entrainment chamber is configured such that at least a portion of inlet aerosol is entrained into the flow of the gas within the entrainment volume to produce an entrained aerosol flow at the outlet port. The particle selection chamber is configured to receive the entrained aerosol flow and produce an outlet aerosol flow. The particle selection chamber and nozzle are collectively configured such that a volumetric median diameter of the outlet aerosol flow is less than a volumetric median diameter of the inlet aerosol.

Abstract: The present invention relates to a dry powder inhaler for administering a medicament via oral inhalation route to a subject. Particularly, the dry powder inhaler according to present invention is suitable for delivering accurate doses of a medicament in different ranges of inspiratory capacity of the subject.

Abstract: The present invention relates to a dry powder inhaler for administering a medicament via oral inhalation route to a subject. Particularly, the dry powder inhaler according to present invention is suitable for delivering accurate doses of a medicament in different ranges of inspiratory capacity of the subject.

Abstract: An aerosol preparation assembly includes an entrainment chamber defining an entrainment volume. The entrainment chamber includes a gas inlet port, an aerosol inlet port and an outlet port. The entrainment chamber is configured such that a velocity of a flow of a gas within the entrainment volume is less than a velocity of the flow of the gas within the gas inlet port. The entrainment chamber is configured such that at least a portion of inlet aerosol is entrained into the flow of the gas within the entrainment volume to produce an entrained aerosol flow at the outlet port. The particle selection chamber is configured to receive the entrained aerosol flow and produce an outlet aerosol flow. The particle selection chamber and nozzle are collectively configured such that a volumetric median diameter of the outlet aerosol flow is less than a volumetric median diameter of the inlet aerosol.

Abstract: An apparatus can include a nasal cannula assembly, which includes a face piece. The face piece includes a plenum portion and a nasal interface portion. The plenum portion is configured to be coupled to a supply line and defines a flow path configured to receive an aerosol flow from the supply line. The nasal interface portion includes a first delivery protrusion and a second delivery protrusion. The first delivery protrusion is configured to convey a first portion of the aerosol flow to a first nostril, and the second delivery protrusion is configured to deliver a second portion of the aerosol flow to a second nostril. The plenum portion includes a sidewall having a curved surface configured to redirect the second portion of the aerosol flow towards the second delivery protrusion. The sidewall is configured to isolate the flow path from a volume downstream from the second delivery protrusion.